iobenguane (123i) Report issue

Small molecule Imaging Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG PubChem

Active Ingredient History

NOW
  • Now
IOBENGUANE I-123 (AdreView®) is a radiopharmaceutical agent for gamma-scintigraphy. It is similar in structure to the antihypertensive drug guanethidine and to the neurotransmitter norepinephrine (NE). IOBENGUANE is, therefore, largely subject to the same uptake and accumulation pathways as NE. It is taken up by the NE transporter in adrenergic nerve terminals and stored in the presynaptic storage vesicles. IOBENGUANE accumulates in adrenergically innervated tissues such as the adrenal medulla, salivary glands, heart, liver, spleen, and lungs as well as tumors derived from the neural crest. By labeling IOBENGUANE with the isotope iodine 123 (I-123), it is possible to obtain scintigraphic images of the organs and tissues in which the radiopharmaceutical accumulates. IOBENGUANE I-123 (AdreView®) is indicated for use in the detection of primary or metastatic pheochromocytoma or neuroblastoma. It is also used for scintigraphic assessment of sympathetic innervation of the myocardium by measurement of the heart to mediastinum (H/M) ratio of radioactivity uptake in patients with New York Heart Association (NYHA) class II or class III heart failure and left ventricular ejection fraction (LVEF) ≤ 35%. Among these patients, IOBENGUANE I-123 (AdreView®) may be used to help identify patients with lower one and two-year mortality risks, as indicated by an H/M ratio ≥ 1.6.   NCATS

Chemistry

More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$1354.5650 - $1582.9150
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

123i metaiodobenzylguanidine | 123i-metaiodobenzylguanidine | 3-iodobenzylguanidine | ((3-iodophenyl)methyl)guanidine | adreview | i-123 metaiodobenzylguanidine | i-123 mibg | i-123-mibg | iobenguane | iobenguane (123i) | iobenguane i 123 | iobenguane i-123 | iobenguane i 123 injection | iobenguane sulfate | iobenguane sulfate (123i) | iobenguane sulfate i 123 | iobenguane sulfate i-123 | iodobenzylguanidine sulfate (123i) | metaiodobenzylguanidine | mibg | mibg-i-123 | m-iodobenzylguanidine

Organizations (23)

Research & Development (23)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (4)


 

Heart Failure (approved 2008)

Neuroblastoma (approved 2008)

Pheochromocytoma (approved 2008)

Ventricular Dysfunction, Left (approved 2008)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Carcinoid Tumor (Phase 3)

Cardiomyopathies (Phase 4)

Heart Failure (Phase 4)

Neuroblastoma (Phase 3)

Neuroendocrine Tumors (Early Phase 1)

Paraganglioma (Phase 3)

Pheochromocytoma (Phase 3)

Thyroid Neoplasms (Phase 3)

Ventricular Dysfunction, Left (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 20
  • # of Trial Organizations: 23

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue